NASDAQ:HZNP

Horizon Therapeutics Public Stock Forecast, Price & News

$107.95
+1.88 (+1.77 %)
(As of 09/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$105.48
$107.96
50-Day Range
$91.91
$110.26
52-Week Range
$66.41
$111.70
Volume1.01 million shs
Average Volume1.60 million shs
Market Capitalization$24.39 billion
P/E Ratio47.98
Dividend YieldN/A
Beta1.08
30 days | 90 days | 365 days | Advanced Chart
Receive HZNP News and Ratings via Email

Sign-up to receive the latest news and ratings for Horizon Therapeutics Public and its competitors with MarketBeat's FREE daily newsletter.


Horizon Therapeutics Public logo

About Horizon Therapeutics Public

Horizon Therapeutics Plc is a biopharmaceutical company, which is engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Rheumatology, and Inflammation segments. The Orphan and Rheumatology segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises of medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

2.15 out of 5 stars

Medical Sector

214th out of 1,352 stocks

Pharmaceutical Preparations Industry

100th out of 665 stocks

Analyst Opinion: 1.4Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Horizon Therapeutics Public (NASDAQ:HZNP) Frequently Asked Questions

Is Horizon Therapeutics Public a buy right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Horizon Therapeutics Public in the last year. There are currently 1 sell rating, 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Horizon Therapeutics Public stock.
View analyst ratings for Horizon Therapeutics Public
or view top-rated stocks.

What stocks does MarketBeat like better than Horizon Therapeutics Public?

Wall Street analysts have given Horizon Therapeutics Public a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Horizon Therapeutics Public wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Horizon Therapeutics Public?

Horizon Therapeutics Public saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 4,090,000 shares, an increase of 21.0% from the August 15th total of 3,380,000 shares. Based on an average trading volume of 1,320,000 shares, the short-interest ratio is currently 3.1 days. Currently, 1.9% of the shares of the company are short sold.
View Horizon Therapeutics Public's Short Interest
.

When is Horizon Therapeutics Public's next earnings date?

Horizon Therapeutics Public is scheduled to release its next quarterly earnings announcement on Monday, November 1st 2021.
View our earnings forecast for Horizon Therapeutics Public
.

How were Horizon Therapeutics Public's earnings last quarter?

Horizon Therapeutics Public Limited (NASDAQ:HZNP) announced its quarterly earnings data on Tuesday, August, 3rd. The biopharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.87 by $0.75. The biopharmaceutical company earned $832.55 million during the quarter, compared to analyst estimates of $697.69 million. Horizon Therapeutics Public had a net margin of 20.27% and a trailing twelve-month return on equity of 27.41%. The firm's quarterly revenue was up 79.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.40 earnings per share.
View Horizon Therapeutics Public's earnings history
.

How has Horizon Therapeutics Public's stock been impacted by Coronavirus (COVID-19)?

Horizon Therapeutics Public's stock was trading at $30.51 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, HZNP stock has increased by 253.8% and is now trading at $107.95.
View which stocks have been most impacted by COVID-19
.

What guidance has Horizon Therapeutics Public issued on next quarter's earnings?

Horizon Therapeutics Public updated its FY 2021 earnings guidance on Wednesday, August, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $3.03 billion-$3.13 billion, compared to the consensus revenue estimate of $2.81 billion.

What price target have analysts set for HZNP?

10 brokerages have issued 1 year target prices for Horizon Therapeutics Public's shares. Their forecasts range from $100.00 to $135.00. On average, they anticipate Horizon Therapeutics Public's share price to reach $118.56 in the next year. This suggests a possible upside of 9.8% from the stock's current price.
View analysts' price targets for Horizon Therapeutics Public
or view top-rated stocks among Wall Street analysts.

Who are Horizon Therapeutics Public's key executives?

Horizon Therapeutics Public's management team includes the following people:
  • Timothy P. Walbert, Chairman, President & Chief Executive Officer (LinkedIn Profile)
  • Paul W. Hoelscher, Chief Financial Officer & Executive Vice President
  • Jeffrey W. Sherman, Chief Medical Officer & Executive Vice President
  • Jeffrey D. Kent, Executive VP-Medical Affairs & Outcomes Research
  • Elizabeth H.Z. Thompson, Executive Vice President-Research & Development

What is Timothy Walbert's approval rating as Horizon Therapeutics Public's CEO?

70 employees have rated Horizon Therapeutics Public CEO Timothy Walbert on Glassdoor.com. Timothy Walbert has an approval rating of 73% among Horizon Therapeutics Public's employees.

Who are some of Horizon Therapeutics Public's key competitors?

What other stocks do shareholders of Horizon Therapeutics Public own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Horizon Therapeutics Public investors own include Alibaba Group (BABA), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), Netflix (NFLX), Gilead Sciences (GILD), Tesla (TSLA), AbbVie (ABBV), Micron Technology (MU) and PayPal (PYPL).

What is Horizon Therapeutics Public's stock symbol?

Horizon Therapeutics Public trades on the NASDAQ under the ticker symbol "HZNP."

Who are Horizon Therapeutics Public's major shareholders?

Horizon Therapeutics Public's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.82%), FMR LLC (6.56%), BlackRock Inc. (6.19%), JPMorgan Chase & Co. (2.66%), State Street Corp (2.41%) and William Blair Investment Management LLC (1.95%). Company insiders that own Horizon Therapeutics Public stock include Andy Pasternak, Barry Moze, Brian K Beeler, Daniel A Camardo, Elizabeth HZ Thompson, Geoffrey M Curtis, Irina Konstantinovsky, Jeff Kent, Jeffrey W Sherman, Michael A Desjardin, Michael G Grey, Miles W Mchugh, Paul W Hoelscher, Timothy P Walbert, Timothy P Walbert, Vikram Karnani and William F Daniel.
View institutional ownership trends for Horizon Therapeutics Public
.

Which major investors are selling Horizon Therapeutics Public stock?

HZNP stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, BNP Paribas Arbitrage SA, Eagle Asset Management Inc., Vanguard Group Inc., American Century Companies Inc., Westfield Capital Management Co. LP, and Marshall Wace North America L.P.. Company insiders that have sold Horizon Therapeutics Public company stock in the last year include Andy Pasternak, Barry Moze, Daniel A Camardo, Elizabeth HZ Thompson, Geoffrey M Curtis, Irina Konstantinovsky, Jeff Kent, Jeffrey W Sherman, Michael A Desjardin, Michael G Grey, Miles W Mchugh, Paul W Hoelscher, Timothy P Walbert, Vikram Karnani, and William F Daniel.
View insider buying and selling activity for Horizon Therapeutics Public
or view top insider-selling stocks.

Which major investors are buying Horizon Therapeutics Public stock?

HZNP stock was acquired by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Macquarie Group Ltd., State Street Corp, Point72 Asset Management L.P., FMR LLC, Bank of Montreal Can, Woodline Partners LP, and Millennium Management LLC.
View insider buying and selling activity for Horizon Therapeutics Public
or or view top insider-buying stocks.

How do I buy shares of Horizon Therapeutics Public?

Shares of HZNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Horizon Therapeutics Public's stock price today?

One share of HZNP stock can currently be purchased for approximately $107.95.

How much money does Horizon Therapeutics Public make?

Horizon Therapeutics Public has a market capitalization of $24.39 billion and generates $2.20 billion in revenue each year. The biopharmaceutical company earns $389.80 million in net income (profit) each year or $3.88 on an earnings per share basis.

How many employees does Horizon Therapeutics Public have?

Horizon Therapeutics Public employs 1,395 workers across the globe.

Does Horizon Therapeutics Public have any subsidiaries?

The following companies are subsidiares of Horizon Therapeutics Public: Andromeda Biotech Limited, Curzion Pharmaceuticals Inc., HZNP Canada Limited, HZNP Finance Limited, HZNP Limited, HZNP USA LLC, Horizon Medicines LLC, Horizon Ophthalmology Inc, Horizon Orphan Holdings LLC, Horizon Orphan LLC, Horizon Pharma Aon Limited, Horizon Pharma Dó Limited, Horizon Pharma Israel Holding Corp. Ltd, Horizon Pharma Rheumatology LLC, Horizon Pharma Trí Limited, Horizon Therapeutics Capital Limited, Horizon Therapeutics Finance Limited, Horizon Therapeutics Finance S.à.r.l, Horizon Therapeutics GmbH, Horizon Therapeutics Holdings Limited, Horizon Therapeutics Investment Limited, Horizon Therapeutics Ireland DAC, Horizon Therapeutics LLC, Horizon Therapeutics Schweiz GmbH, Horizon Therapeutics Services LLC, Horizon Therapeutics Treasury DAC, Horizon Therapeutics USA Inc., Hyperion Therapeutics Ireland Holding Limited, Hyperion Therapeutics Ireland Operating Limited, and River Vision Development Corp..

When was Horizon Therapeutics Public founded?

Horizon Therapeutics Public was founded in 2008.

What is Horizon Therapeutics Public's official website?

The official website for Horizon Therapeutics Public is www.horizontherapeutics.com.

Where are Horizon Therapeutics Public's headquarters?

Horizon Therapeutics Public is headquartered at 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6.

How can I contact Horizon Therapeutics Public?

Horizon Therapeutics Public's mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. The biopharmaceutical company can be reached via phone at (531) 772-2100 or via email at [email protected]


This page was last updated on 9/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.